Internet and Psychiatry
  • Home
    • Editorials
    • Research news
    • Research papers
    • Interviews with eminent psychiatrists
    • Ten years ago
    • Fifteen years ago
  • Topics
    • Alcohol and Drug Abuse
    • Anxiety Disorders
    • Biomedical Science
    • Compulsive gambling
    • Disaster Medicine
    • Education
    • General Medicine
      • Acupuncture
      • Physical medicine and Rehabilitation
    • Human Rights
    • Interviews with eminent psychiatrists
    • Mood Disorders
      • Bipolar Disorder
      • Depression
      • Seasonal Affective Disorder
    • Neurological Disorders
    • Other Psychiatric Disorders
    • Posttraumatic Stress Disorder
    • Sexual Behavior
  • Books
    • Comorbidity of Depression and Alcohol Use Disorders
    • “Immigration and Mental Health” chapter abstracts
    • “Internet and Suicide” chapter abstracts
    • “Neurobiology of PTSD” chapter abstracts
    • “Suicidal Behavior in Alcohol…” chapter abstracts
    • “Suicide in the Military” chapter abstracts
    • “Terror and Suicide” chapter abstracts
    • “War and Suicide” chapter abstracts
  • Editors
    • Leo Sher, M.D.
    • Alexander Vilens, M.S.
  • Guests
    • Distinguished Guests
    • Our Contributors
  • Reflections
    • Poetry
    • Quotes

Research news

Traumatic memory reactivation with or without propranolol for PTSD and comorbid major depression symptoms

March 21, 2021

Leo Sher, M.D.

A research report, “Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial” has been published in Neuropsychopharmacology online ahead of print (1). The authors aimed to examine the efficacy of traumatic memory reactivation under the influence of propranolol in reducing PTSD symptoms as well as comorbid major depression (MD) symptoms.

Researchers performed a double blind, placebo-controlled, randomised clinical trial in 66 adults diagnosed with PTSD. Propranolol or a placebo was administered 90 minutes before a brief memory reactivation session, once a week for 6 consecutive weeks. Measures included the SCID PTSD module, the PTSD Check List (PCL-S) and the Beck Depression Inventory-II (BDI-II).

PTSD symptoms decreased both in the pre-reactivation propranolol group (39.28%) and the pre-reactivation placebo group (34.48 %). During the 6 treatment sessions, PCL-S and BDI-II scores decreased to similar extent in both groups and there were no treatment differences. During the 3-month follow-up period, there were no treatment effects for the mean PCL-S and BDI-II scores. However, in patients with severe PTSD symptoms (PCL-S ≥ 65) before treatment, PCL-S and BDI-II scores continued to decline 3 months after the end of treatment in the propranolol group while they increased in the placebo group.

The authors concluded that repeated traumatic memory reactivation seemed to be effective for PTSD and comorbid MD symptoms. The efficacy of propranolol was not greater than that of placebo one week after treatment. However, propranolol seemed to be effective in stabilising improvement in patients with severe PTSD.

Reference

1. Roullet P, Vaiva G, Véry E, Bourcier A, Yrondi A, Dupuch L, Lamy P, Thalamas C, Jasse L, El Hage W, Birmes P. Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms: a randomised clinical trial. Neuropsychopharmacology. 2021 Feb 21:1–7. doi: 10.1038/s41386-021-00984-w. Epub ahead of print.

Related Posts

Research news /

Mortality rates for buprenorphine versus methadone treatments

Research news /

Brain-derived neurotrophic factor levels in combat veterans with or without a history of suicide attempt

Research news /

Pro-inflammatory cytokines and suicidality in patients with bipolar disorder

‹ Short sleepers live under higher homeostatic sleep pressure than long sleepers › Alcohol use and suicide rates in young people

Editorials

  • Monkeypox: A psychiatrist’s guide
  • Fluvoxamine attenuates COVID-19 disease
  • What? Botox injections can mitigate depressions?
  • Smoking, suicide risk, and the COVID-19 pandemic

Research Papers

  • COVID-19 mortality in Europe and the ’Iron Curtain’ between East and West
  • Examination of depressive signs and symptoms among 803 University students in seven Universities and Colleges. Hungary, Romania, Serbia.
  • Examination of spirituality and the dimensions of spirituality among 803 students in seven different Universities. Hungary, Romania and Serbia.
  • Examination of depressive signs and symptoms among 932 students in eight different secondary schools in Hungary

Research News

  • Mortality rates for buprenorphine versus methadone treatments
  • Brain-derived neurotrophic factor levels in combat veterans with or without a history of suicide attempt
  • Pro-inflammatory cytokines and suicidality in patients with bipolar disorder
  • Thirty years of publications in the field of suicidology

Latest News

  • Leading world experts on suicide. Expertscape, the June 20, 2022, report
  • The U.S. Department of Veterans Affairs offers large prizes for suicide prevention ideas
  • Suicide mortality in the U.S. decreased from 2018 to 2020 after increasing since 2000
  • The World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Men’s Mental Health – January 2022 update

Interviews with eminent psychiatrists

  • Interview with Professor Shih-Ku Lin
  • Interview with Professor Masahito Fushimi
  • Interview with Professor Maurizio Pompili
  • Interview with Professor Marco Sarchiapone

Ten Years Ago

  • Teaching medical professionals and trainees about suicide prevention
  • Suicidal ideation in depressed patients with or without comorbid posttraumatic stress disorder treated with selective serotonin reuptake inhibitors
  • Treatment of suicide attempters with bipolar disorder: a randomized clinical trial
  • Posttraumatic stress disorder and the Neuroevolutionary Time-depth Principle

Back to Top

  • About
  • Contact
  • Privacy Policy
  • Terms and Conditions
Copyright © 2022 AVCalc LLC. All rights reserved worldwide.